ReviewVascular health and risk management2010
Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review.
Review in Vascular health and risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Pooled it
- Efficacy and Safety of a Generic Clevidipine in Hypertensive Urgencies and Non-Fulminant Hypertensive Emergencies: A Phase III, Multicenter, Randomized, Double-Blind, Positive Drug Parallel-Controlled Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Calcium Channel Blockers in Critical Care Medicine: Current Clinical Applications and Future Investigational Perspectives.Medical sciences (Basel, Switzerland) · 2026Review
- Proposal of a Modified Classification of Hypertensive Crises: Urgency, Impending Emergency, and Emergency.Current vascular pharmacology · 2024Review
- Simultaneous Quantitation of Clevidipine and Its Active Metabolite H152/81 in Human Whole Blood by LC-MS/MS: Application to Bioequivalence Study.Frontiers in chemistry · 2022Article
- Review
- Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.ACS infectious diseases · 2019Review
- The expanding role of prodrugs in contemporary drug design and development.Nature reviews. Drug discovery · 2018Review
- Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings.Drugs · 2014Review
- Newer therapies in the operative management of phaeochromocytoma.Indian journal of endocrinology and metabolism · 2013Article
- Control of hypertension in the critically ill: a pathophysiological approach.Annals of intensive care · 2013Article
- 1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.Translational medicine @ UniSa · 2012Article
- Advances in management of acute hypertension: a concise review.Discovery medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acutely elevated blood pressure in the critical care setting is associated with a higher risk of acute end-organ damage (eg, myocardial ischemia, stroke, and renal failure) and perioperative bleeding. Urgent treatment and careful blood pressure control are crucial to prevent significant morbidity. Clevidipine butyrate (Cleviprex) is an ultrashort-acting, third-generation intravenous calcium channel blocker. It is an arterial-selective vasodilator with no venodilatory or myocardial depressive effects. Clevidipine has an extremely short half-life of approximately 1 minute as it is rapidly metabolized by blood and tissue esterases. These metabolites are then primarily eliminated through urine and fecal pathways. The rapid onset and the short duration of action permit tighter and closer adjustment of the blood pressure than is possible with other intravenous agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.